Svetlana N. Styazhkina - Professor of the department of faculty surgery, MD, PhD.

Aim of the research: The research aims to study destructive processes of pancreatic tissue, extrapancreatic lesion in experimental sharp destructive pancreatitis (ESDP) with immune-correcting medication, protease inhibitor, non-steroidal antiinfl ammatory agent.

Materials and methods. Modelling of ESDP was carried out on laboratory rodents and involved peroral use of 1.0–1.5 ml of proof spirit 40% during 90 days, with the follow-up (after 60 days) introduction of fad nutrition. The research engaged three groups: group 1 was treatment group (index group) and groups 2 and 3 were experimental groups. The group 1 did not get any pharmacological treatment. Group No.2 got daily i ntravenous dose of 1.0 1000 KIU of aprotinin into the tail vein and peroral azoximer bromide of 3 mg. Group 3 was treated with daily intramuscular injection of diclofenac of 0.1 ml 2.5% into femoral region and intravenous dose of 1.0 1000 KIU of aprotinin. Removal from the experiment was made in 60th and 90th days with the pathomorphological study of lesion in cells of pancreas, parapancreatic structures, kidneys, peritoneum, mesentery.

Research results and discussion.   In histopathological examination of tissues of pancreas the overt edema, paravasal neu-trophil infi ltration, focal areas of subtotal necrosis were observed on the 60th day of experiment in treatment (index) group 1, whereas groups 2 and 3 showed less evident  pathomorphologicallesion and pancreatic necrosis was of focus nature. In histopathological examination of tissues on the 90th day, the pancreatic necrosis was retained and  extrapancreatic compli-cations in kidneys, kidneys, intestine, peritoneum and mesentery were observable in groups 1 and 2. Pathomorphological lesion was less overt in group 3.

Conclusions. Combination of pharmacological medication has a significant impact on destructive processes in pancreas and the development of extrapancreatic complications. One way to develop endogenic impairment is enterogenous that is less responsive to medical treatment.

1. Acute pancreatitis. Clinical recommendation MH RF. 2019. P. 6.

2. Rakhimov R. R. Complex approach to diagnostics and management of infected pancreatonecrosis. Permian medical journal. 2016; XXXIII(6):36–41.

3. Munigala S., Yadav D. Case–fatality from acute pancreatitis is decreasing but its population shows little change. Pancreatologie. 2016;16 (4): 512–550.

4. Seidi W., Sterel H., Depisch D. Die bilivre Pankreatitis neue Behandlungkonzepte. Ada chir. Austriaca. 2017, vol.21, no.4, pp. 225–259.

5. Bagnenko S. F., Golcov V. R., Savello V. E., Vashetko R. V. Classifi cation of acute pancreatitis: current status of problem. Grekov’s Bulletin of Surgery. 2015, Vol.174. no. 5, pp. 86–92.

6. Rodoman G. V. Systemic disorders management in patients with acute pancreatic necrosis. Pirogov Russian Journal of Surgery. 2016, no. 11.

7. Ermolov A. S. Longterm results of severe acute pancreatitis management. Th e surgery. 2016, no.10, pp. 11–15

8. Romanov E. I. Risk factors of fatal outcome in pancreatonecrosis. Grekov’s Bulletin of Surgery. 2014, Vol.173, no.4, pp.39–42

9. Lyzikov A. N. Morphological features of extrapancreatic lesion of internal organs in acute enzymatic parapancre-atitis. Problems of health and ecology. 2014;1(39):61–66.

10. Akimov A. A. et al. Acute pancreatitis in young age/ Th e Journal of scientific articles «Health and Education Millennium». 2018, Vol. 20, no. 4, pp.18–21.

11. Kovshik G. G., Khrapova M. V., Dushkin M. I. Peculiarities of lipid and glucose metabolism in hypertensive rats of starin ISIAH. Siberian scientific medical journal. 2013, Vol. 33, no.4, pp. 5–11.